BioChaperone CagriSema | News Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

112 results for “BioChaperone CagriSema”

Adocia Files Patent for AdoXLong Platform to Extend Peptide Therapy Duration to Monthly Injections

Adocia Secures €9.7 Million Private Placement to Advance Diabetes and Obesity Pipeline Through Q2 2026

Adocia to Host Virtual KOL Event Reviewing Phase 3 Results of Ultra-Rapid Insulin BioChaperone Lispro in Type 2 Diabetes

Adocia's Ultra-Rapid Insulin BioChaperone Lispro Meets Primary Endpoint in Phase 3 Trial for Type 2 Diabetes

Novo’s CagriSema Disappoints in Pivotal Trial

Novo Nordisk Delays CagriSema Obesity Drug Filing to Early 2026

Novo Nordisk's CagriSema Falls Short Against Eli Lilly's Tirzepatide in Obesity Trial

CagriSema Fails to Meet Primary Endpoint in Phase III Clinical Trial for Obesity

Novo Nordisk's CagriSema Outperforms Ozempic in Diabetes Trial, Company Plans Pediatric Obesity Study

Novo Nordisk's CagriSema Shows Promise in Weight Loss and Diabetes Treatment

Page 1 of 5